Page 12 - Mark Foundation News Today

Evotec SE reports results for the first quarter 2021 and provides corporate update SUCCESSFUL START TO 2021 WITH STRONG STRATEGIC POSITION AND LONG-TERM STRATEGY: ACTION PLAN 2025 THE DATA-DRIVEN R&D AUTOBAHN TO CURES GOOD PROGRESS WITHIN PRODUCT DEVELOPMENT PARTNERSHIPS AND CO-OWNED PORTFOLIO CONTINUED POSITIVE FINANCIAL PERFORMANCE; NO MATERIAL IMPACT THROUGH COVID-19 PANDEMIC Hamburg, Germany, 11 May 2021: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664...

EVOTEC SE REPORTS RESULTS FOR THE FIRST QUARTER 2021 AND PROVIDES CORPORATE UPDATE DGAP-News: Evotec SE / Key word(s): Quarter Results/Quarterly / Interim Statement 11.05.2021 / 07:00   SUCCESSFUL START TO 2021 WITH STRONG STRATEGIC POSITION AND LONG-TERM STRATEGY: ACTION PLAN 2025 "THE DATA-DRIVEN R&D AUTOBAHN TO CURES" GOOD PROGRESS WITHIN PRODUCT DEVELOPMENT PARTNERSHIPS AND CO-OWNED PORTFOLIO CONTINUED POSITIVE FINANCIAL PERFORMANCE; NO MATERIAL IMPACT THROUGH COV...

AlleyWatch C2i Genomics C2i Genomics is provides cloud-based cancer diagnostic services to pharmaceutical and diagnostic organizations. Founded by Boris Oklander, C2i Genomics is backed by investors that include Casdin Capital, NFX, and The Mark Foundation for Cancer Research and is headquartered in New York. INDUSTRY:Health Care, Pharmaceutical

April 19, 2021 In a study by Yale Cancer Center, researchers report on the discovery of a common mechanism that promotes both autoimmune diseases and blood cancers, including the blood diseases Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL). The results could help scientists better understand disease origin and progression in patients. The paper is published online today in the journal Molecular Cell. “Our findings are very exciting in t...

Alliance for Cancer Gene Therapy Summit 2021 Features World Renowned Cancer Researchers Advancing Solid Tumor Breakthroughs Share Article James P. Allison, PhD, Carl H. June, MD and Siddhartha Mukherjee, MD Keynote April 29 Summit Nobel Laureate James P. Allison, PhD, Carl H. June, MD and Pulitzer-prize winning author Siddhartha Mukherjee, MD will be the keynote speakers at the virtual Alliance for Cancer Gene Therapy Summit It’s so rare to have the opportunity to hear from the world’s top ...

Experts to discuss advanced cancer cell and gene therapies at Summit 2021 April 29 marks a pivotal moment in cancer research when the worlds brightest minds come together to discuss how to translate the success of CAR T-cell therapies for blood cancers into successful cell and gene therapies for the most complex and deadly solid tumor cancers. The scientists and companies driving the latest advances in cancer cell and gene therapy will gather online for a virtual Summit with the Alliance for Ca...

C2i Genomics, a New York, NY-based cancer intelligence company, raised $100m in financing. The round was led by Casdin Capital with participation from NFX, Duquesne Family Office, Section 32, iGlobe Partners, Driehaus Capital and others. The financing was executed as a convertible note with two tranches of $50m, called by the company with additional participation from The Mark Foundation for Cancer Research, Silver Lake, Alexandria Real Estate, Gordon Asset Management, and LionBird.  The comp...

 E-Mail BOSTON - A gene called KRAS is one of the most commonly mutated genes in all human cancers, and targeted drugs that inhibit the protein expressed by mutated KRAS have shown promising results in clinical trials, with potential approvals by the U.S. Food and Drug Administration anticipated later this year. Unfortunately, cancer cells often develop additional mutations that make them resistant to such targeted drugs, resulting in disease relapse. Now researchers led by a team at Massachus...

share: This news release, issued by Johns Hopkins Medicine, describes a novel targeted immunotherapy approach. This new approach employs bispecific antibodies to treat cancer by eliciting a Tcell response against mutated p53. The researchers used the Highly Automated Macromolecular Crystallography (AMX) and Frontier Microfocusing Macromolecular Crystallography (FMX) beamlines to characterize the molecular structure of the proteins. AMX and FMX are beamlines at the National Synchrotron Li...

Diabodies see the unseeable RAS oncogene mutations are common in various cancers, controlling their growth and survival. Targeting mutant RAS proteins with antibodies has been unsuccessful due to low surface expression, even when targeting mutant RAS peptides presented via HLA on the surface of cancer cells. Douglass et al. used phage display to generate single-chain variable fragments (scFvs) specific for mutant RAS peptide-HLA complexes. The authors tested various bispecific, T cell–engagi...